Genetics of Fatty Liver Disease in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01966627|
Recruitment Status : Completed
First Posted : October 21, 2013
Last Update Posted : December 8, 2017
This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents.
Hypothesis 1: Common variants recently associated with variation in plasma TG levels identified in Genome Wide Association Studies (GWAS) (such as GCKR, PNPLA3) can affect accumulation of fat and subsequent development of Non Alcoholic Fatty Liver Disease (NAFLD). Gene variants act in additive or synergistic manner with progressive liver fat accumulation per additional risk allele.
Hypothesis 2: With increase in hepatic fat content NASH and fibrosis will increase. Furthermore, expression of lipogenic markers (SREBP1c) will increase.
|Condition or disease||Intervention/treatment|
|Non Alcoholic Fatty Liver Disease||Other: ogtt Other: genotyping Other: abdominal and liver magnetic resonance imaging Other: stool sample Other: liver biopsy|
|Study Type :||Observational|
|Actual Enrollment :||381 participants|
|Official Title:||Genetics of Fatty Liver Disease in Childhood Obesity.|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||July 2017|
|Actual Study Completion Date :||July 2017|
Pediatric NAFLD Cohort
Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
oral glucose tolerance test
genotyping to look for risk alleles
Other: abdominal and liver magnetic resonance imaging
magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
Other: stool sample
stool sample taken to investigate metabolites
Other: liver biopsy
liver biopsy to examine for cellular change and steatosis
- gene expression [ Time Frame: Baseline ]gene mutation allele variation identification measure via gene extraction
- hepatic fat content [ Time Frame: 2 years ]Abdominal MRI to measure liver fat and subcutaneous and visceral fat ratio done at baseline and 2 year follow up
- glucose tolerance [ Time Frame: 2 years ]glucose tolerance status measured by 3 hour oral glucose tolerance test done at baseline and 2 year follow up
- DNA gene sequencing of intestinal bacteria's [ Time Frame: 2 years ]Measure microbiota diversity via stool samples to understand variance of triglycerides accumulation in liver
- Use liver biopsy specimen to assess differences in gene expression, as well as inflammation. [ Time Frame: As indicated by Pediatric Hepatolgist ]liver biopsy tissue obtained when subject is scheduled for pre-ordered biopsy by hepatologist
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01966627
|United States, Connecticut|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Sonia Caprio, M.D.||Yale University|